Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the...
American College of Cardiology Aug 30 2024 Semaglutide , the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss , including reducing risk of death, reducing serious COVID-19 related events and improving heart failure symptoms, according to six new substudies published in JACC, the flagship journal of the American College of Cardiology .
Semaglutide improves CV outcomes regardless of sex, reduces COVID-19 related death in patients with obesity and CVD In two new substudies of the SELECT Trial, which included people who had overweight or obesity according to BMI and had established cardiovascular disease but not diabetes, researchers looked at whether once weekly semaglutide reduced rates of all-cause death, CV death and non-CV death, including death from COVID-19, and whether sex impacts the efficacy and safety of the...
Semaglutide reduces risk of HF events in people with diabetes and chronic kidney disease Having both Type 2 diabetes and chronic kidney disease can increase the risk of HF and death compared to each condition alone. Semaglutide was previously shown to reduce the risk of major kidney disease events in this population, and in a new substudy from the FLOW trial, researchers looked at the effects of semaglutide on HF in this high-risk group.
Semaglutide Weight Loss Atrial Fibrillation Cardiology Chronic Chronic Kidney Disease Covid-19 Diabetes Efficacy GLP-1 Heart Failure Inflammation Kidney Kidney Disease Medicine Obesity Placebo Protein Research
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Study finds weight loss drug semaglutide reduced COVID-19 related deaths during the pandemicPatients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, finds.
Weiterlesen »
Semaglutide reduces COVID-19 related deaths in patients with obesity and cardiovascular diseaseSemaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease (CVD) without diabetes, according to a new study published in JACC.
Weiterlesen »
Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesitySemaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.
Weiterlesen »
Semaglutide products being sold online without prescriptionsSemaglutide products are being sold online, with products likely unregistered or unlicensed, according to a research letter published online Aug. 2 in JAMA Network Open.
Weiterlesen »
Semaglutide-linked suicidal ideation identified in disproportionality analysisSemaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open.
Weiterlesen »
Clarification urgently needed for detected signal of semaglutide-linked suicidal ideationResearchers investigate the potential link between the obesity drugs semaglutide and liraglutide and suicidal or self-injurious adverse drug reactions.
Weiterlesen »